4.1.1.17: ornithine decarboxylase
This is an abbreviated version!
For detailed information about ornithine decarboxylase, go to the full flat file.
Word Map on EC 4.1.1.17
-
4.1.1.17
-
polyamine
-
spermidine
-
alpha-difluoromethylornithine
-
carcinogenesis
-
antizyme
-
chemopreventive
-
12-o-tetradecanoylphorbol-13-acetate
-
phorbol
-
mucosa
-
difluoromethylornithine
-
diamine
-
decarboxylases
-
n1-acetyltransferase
-
hyperplasia
-
arginase
-
c-myc
-
antiproliferative
-
tpa-induced
-
prostaglandin
-
testosterone
-
3hthymidine
-
tumorigenesis
-
mitogen
-
cycloheximide
-
c-fos
-
methylglyoxal
-
tpa-treated
-
1,2-dimethylhydrazine
-
isoproterenol
-
hairless
-
degrons
-
12-o-tetradecanoyl
-
hepatectomy
-
cadaverine
-
s-adenosyl-l-methionine
-
drug development
-
azoxymethane
-
protooncogene
-
papilloma
-
7,12-dimethylbenzaanthracene
-
agmatine
-
phorbol-13-acetate
-
medicine
-
tumor-promoting
-
food industry
-
diagnostics
-
nitrilotriacetate
-
pharmacology
-
prolactin
-
crypt
-
trypanothione
-
12-o-tetradecanoylphorbol
-
ester-induced
-
actinomycin
-
mezerein
- 4.1.1.17
- polyamine
- spermidine
- alpha-difluoromethylornithine
- carcinogenesis
- antizyme
-
chemopreventive
- 12-o-tetradecanoylphorbol-13-acetate
-
phorbol
- mucosa
- difluoromethylornithine
-
diamine
- decarboxylases
-
n1-acetyltransferase
- hyperplasia
- arginase
- c-myc
-
antiproliferative
-
tpa-induced
- prostaglandin
- testosterone
-
3hthymidine
- tumorigenesis
-
mitogen
- cycloheximide
- c-fos
- methylglyoxal
-
tpa-treated
- 1,2-dimethylhydrazine
- isoproterenol
- hairless
- degrons
-
12-o-tetradecanoyl
-
hepatectomy
- cadaverine
- s-adenosyl-l-methionine
- drug development
- azoxymethane
-
protooncogene
- papilloma
-
7,12-dimethylbenzaanthracene
- agmatine
- phorbol-13-acetate
- medicine
-
tumor-promoting
- food industry
- diagnostics
- nitrilotriacetate
- pharmacology
- prolactin
-
crypt
- trypanothione
-
12-o-tetradecanoylphorbol
-
ester-induced
- actinomycin
- mezerein
Reaction
Synonyms
AdoMetDC/ODC, BN36_1212510, bODC, DDB_G0281109, DdODC, Decarboxylase, ornithine, dODC, LDC/ODC, LdODC, lysine/ornithine decarboxylase, ODC, ODC-paralogue, ODC1, ornithine decarboxylase, PfAdoMetDC-ODC, PfODC/AdoMetDC, S-adenosylmethionine decarboxylase/ornithine decarboxylase, SpeC, XODC1, XODC2, YODC
ECTree
Advanced search results
Application
Application on EC 4.1.1.17 - ornithine decarboxylase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
diagnostics
drug development
medicine
pharmacology
-
a single nucleotide polymorphism in intron 1 of the ODC gene serves as genetic marker for colon cancer
diagnostics
-
ODC can be useful in gene diagnosis and gene therapy of cancers, since some chemotherapeutic agents aim at reducing ODC expression and show inhibitory effects on cancer cell growth
diagnostics
-
ODC may be used as a good biomarker in the screening and diagnosis of precancerous lesions
diagnostics
-
the naturally occuring ODC G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention
diagnostics
ODC1 expression is associated with worse overall survival and increased recurrence in three endometrial cancer gene expression datasets
-
the enzyme ODC is a drug target in human malignancies, such as skin cancer
drug development
-
the enzyme of the parasite is a potential target for the development of new drugs for treatment of disease such as African sleeping sickness
drug development
-
the enzyme of the parasite is a potential target for the development of new drugs for treatment of diseases such as African sleeping sickness or Chagas disease
drug development
-
the enzyme of the parasite is a potential target for the development of new drugs for treatment of diseases such as African sleeping sickness or cutaneous leishmaniasis
drug development
-
the enzyme of the parasite is a potential target for the development of new drugs for treatment of diseases such as African sleeping sickness or visceral leishmaniasis
drug development
-
pharmacological inhibition of ODC is a promising therapeutic paradigm for the treatment of visceral and perhaps other forms of leishmaniasis
drug development
the enzyme is a potential anticancer target for inhibitor development
drug development
-
the ODC gene might act as a prognostic factor for breast cancer and it could be a promising therapeutic target for cancer research
drug development
because ODC is essential for trypanothione biosynthesis, polyamines of parasitic protozoa may be potential targets for the development of drugs with activity against Leishmania donovani. One goal of drug development is to evaluate the potential of Leishmania antigen for evoking a Th1 response against Leishmania infection
drug development
-
pharmacological inhibition of ODC is a promising therapeutic paradigm for the treatment of visceral and perhaps other forms of leishmaniasis
-
-
after induction of regenerative hyperplasia or renal hypertrophy by administration of folates or testosterone resp., enzyme activity increases 80- to 1000fold in enzyme activity
medicine
-
assay to quantify enzyme levels in formalin-fixed tumor tissues, semiquantitation of tumor-specific variations of enzyme levels
medicine
-
enzyme is overexpressed in prostate of patients suffering from benign prostatic hyperplasia and overexpression is also an early event in prostate carcinogenesis. Prostate-specific overexpression of enzyme in transgenic mice is not sufficient to induce carcinogenesis
medicine
-
Helicobacter pylori-infected gastric mucosa, oral administation of Lactobacillus brevis induces a decrease in gastric enzyme activity and polyamine levels
medicine
-
ODC can be useful in gene diagnosis and gene therapy of cancers, since some chemotherapeutic agents aim at reducing ODC expression and show inhibitory effects on cancer cell growth
medicine
-
ODC inhibition enhances the anti-tumor effect of antiangiogenesis therapy
medicine
-
polyamine-depletion as an antimalarial strategy, cytostasis caused by the co-inhibition of S-adenosylmethionine decarboxylase/ornithine decarboxylase in Plasmodium falciparum
medicine
-
high ODC mRNA expression shows significant correlation with poor survival prognosis in Kaplan-Meier analyses, elevated ODC mRNA expression level correlates with several unfavorable genetic and clinical features in neuroblastoma
medicine
-
low levels of timorous ODC expression are associated with a more aggressive tumor biology
medicine
-
ODC1 single nucleotide polymorphism may be protective for colon adenoma recurrence and detrimental for survival after colon cancer diagnosis
medicine
-
the rs2302615 single nucleotide polymorphism in the ODC gene is not a risk factor for breast cancer
medicine
-
ornithine decarboxylase and sepiapterin reductase physically interact. In a cohort of 88 human neuroblastoma tumors, high sepiapterin reductase mRNA expression correlates significantly with poor survival prognosis, suggesting an oncogenic role for sepiapterin reductase in neuroblastoma tumorigenesis
medicine
ornithine decarboxylase is a therapeutic target for endometrial cancer. Some endometrial cancers appear particularly sensitive to DL-alpha-difluromethylornithine and the polyamine pathway in endometrial cancers in general and specifically those most likely to suffer adverse clinical outcomes can be targeted for effective treatment, chemoprevention or chemoprevention of recurrence
medicine
targeting both polyamine biosynthesis via ODC through 2-difluoromethylornithine and polyamine transport through MQT 1426 from the tumor microenvironment enhances the efficacy of polyamine-based therapy in this mouse model of squamous cell carcinoma, overview
medicine
-
targeting both polyamine biosynthesis via ODC through 2-difluoromethylornithine and polyamine transport through MQT 1426 from the tumor microenvironment enhances the efficacy of polyamine-based therapy in this mouse model of squamous cell carcinoma, overview
-
-
the enzyme is a target in the combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor MQT 1426, i.e. D-Lys-spermine, against murine squamous cell carcinoma, overview
pharmacology
-
the enzyme ODC is possibly useful in chemotherapy of human malignancies, such as skin cancer
pharmacology
-
pharmacological inhibition of ODC is a promising therapeutic paradigm for the treatment of visceral and perhaps other forms of leishmaniasis
pharmacology
-
the enzyme is a target in the combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor MQT 1426, i.e. D-Lys-spermine, against murine squamous cell carcinoma, overview
-
pharmacology
-
pharmacological inhibition of ODC is a promising therapeutic paradigm for the treatment of visceral and perhaps other forms of leishmaniasis
-